APA (7th ed.) Citation

VK, R., JD, V., HJ, M., WC, W., SS, P., S, Z., . . . A, A. (2026). Risk of kidney failure and death associated with target-dose (vs. below-target-dose) RAS inhibitors in HFrEF, HFmrEF and HFpEF: Spline-based reassessment of subgroup findings. The American journal of medicine, 139(5), e152. https://doi.org/10.1016/j.amjmed.2026.01.035

Chicago Style (17th ed.) Citation

VK, Raman, et al. "Risk of Kidney Failure and Death Associated with Target-dose (vs. Below-target-dose) RAS Inhibitors in HFrEF, HFmrEF and HFpEF: Spline-based Reassessment of Subgroup Findings." The American Journal of Medicine 139, no. 5 (2026): e152. https://doi.org/10.1016/j.amjmed.2026.01.035.

MLA (9th ed.) Citation

VK, Raman, et al. "Risk of Kidney Failure and Death Associated with Target-dose (vs. Below-target-dose) RAS Inhibitors in HFrEF, HFmrEF and HFpEF: Spline-based Reassessment of Subgroup Findings." The American Journal of Medicine, vol. 139, no. 5, 2026, p. e152, https://doi.org/10.1016/j.amjmed.2026.01.035.